Status:
UNKNOWN
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborating Sponsors:
Beijing Hospital
Jiangsu Cancer Institute & Hospital
Conditions:
Advanced Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a multi-center, retrospective, real-world study. The purpose of this study is to observe the effectiveness and safety of regorafenib in Chinese advanced colorectal cancer patients. The main o...
Eligibility Criteria
Inclusion
- Patients with colorectal cancer confirmed by pathological tissue or cytology；
- The pathological type of colorectal tumor was adenocarcinoma；
- Patients with recurrent or metastatic, unresectable advanced colorectal cancer；
- Patients who received regorafenib at least one period treatment.
Exclusion
- Patients participating in other interventional clinical studies while taking regorafenib;
- Patients with other malignant tumors within 5 years before regorafenib treatment, except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal cell carcinoma, early papillary thyroid carcinoma, etc.;
- The investigator deems that there are other factors that are not suitable for patients who participate in this study.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT04835324
Start Date
October 1 2020
End Date
October 1 2022
Last Update
March 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital,Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
2
National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College
Beijing, China, 100021